By Jennifer Chiou
New York, March 21 - APT Pharmaceuticals announced it raised $9 million in a series A round of financing.
Charter Life Sciences and Research Corporation Technologies co-led the financing and Vivo Ventures participated in the final close.
"The additional capital will enable us to accelerate our pulmonary and nasal clinical development programs," APT president Gino Di Sciullo said in a news release.
Based in Tucson, Ariz., APT is a clinical-stage biopharmaceutical company that develops steroid-alternative therapies as well as asthma and autoimmune drugs based on hydroxychloroquine, a disease modifying antirheumatic drug.
| Issuer: | APT Pharmaceuticals
|
| Issue: | Preferred stock
|
| Amount: | $9 million
|
| Round: | Series A
|
| Investors: | Charter Life Sciences (co-lead), Research Corporation Technologies (co-lead); Vivo Ventures
|
| Announcement date: | March 21
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
